Skip to main content
OpenTrials
Completed

NCT Number: NCT02489292

Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002)

The aim of the study is to assess the efficacy of HepaStem treatment in paediatric patients suffering from urea cycle disorders.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Cliniques Universitaires Saint-Luc, Brussels, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Main Inclusion Criteria:

  • Paediatric patients < 12 years prior to infusion
  • Patient presents with UCD
  • Patient shows patency of the portal vein and branches, with normal flow velocity as confirmed by Doppler US and accessibility of the portal vein and /or affluants.

Main Exclusion Criteria:

  • Patient has mild disease severity, easily controlled under standard of care therapy, with no recurrent metabolic crises.
  • Patient is registered on a liver transplant waiting list or is scheduled for living donor liver transplantation before the end of the study.
  • Patient presents acute liver failure.
  • Patient presents clinical or radiological evidence of liver cirrhosis.
  • Patient presents or has a history of hepatic or extrahepatic malignancy.
  • Patient has a known clinically significant cardiac malformation.
  • Patient has a personal history of venous thrombosis, or has a clinically significant abnormal value for protein S, protein C, anti-thrombin III, and /or activated Protein C Resistance (aPCR) at screening. In case of known family history, a complete coagulation work-up should be performed. In all above described cases, results need to be discussed with PB before enrolling the patient in the study.
  • Patient had or has a renal insufficiency treated by dialysis.

Treatment and study plan

HepaStem

Biological

HepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight

Primary outcomes

  1. Efficacy as determined by de novo ureagenesis (C13 tracer method)

    Time frame: at 6m post-first infusion day

Secondary outcomes

  1. Efficacy as determined by de novo ureagenesis (C13 tracer method)

    Time frame: at 3, 9 and 12 months post-first infusion day

  2. Efficacy as determined by Ammonia (NH3) values

    Time frame: up to 12 months post-first infusion day

  3. Efficacy as determined by amino acids in plasma

    Time frame: up to 12 months post-first infusion day

  4. Efficacy as determined by report of metabolic decompensations

    Time frame: up to 12 months post-first infusion day

  5. Efficacy as determined by report on actual supportive treatment, adjustment of protein restriction and amino acids supplements

    Time frame: up to 12 months post-first infusion day

  6. Efficacy as determined report on behavior, cognitive skills and health-related quality-of-life indicators

    Time frame: up to 12 months post-first infusion day

  7. To evaluate the safety during the year following HepaStem infusions (composite)

    Time frame: up to 12 months post-first infusion day

    Safety evaluation in terms of (1) clinical status, (2) portal vein hemodynamics, (3) morphology of the liver, bile ducts and portal system, (4) laboratory tests, (5) De novo detection of donor-specific circulating anti-human leukocyte antigen (HLA) antibodies, and/or other immune-related markers, (6) serious adverse events and clinically significant adverse events related to HepaStem, technical intervention, and concomitant treatments.

Sponsors and collaborators

Lead sponsor

Cellaion SA

Industry

Registry information

Official study title

Prospective, Open Label, Multicenter, Efficacy and Safety Study of Several Infusions of HepaStem in Urea Cycle Disorders Paediatric Patients

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Jul 3, 2015
Registry last updated
Oct 19, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.